Blogs

 

Latest News

Wednesday September 02, 2020

We welcome our new ASI Sustaining Member: Nanostring

 

Our ASI Sustaining Members recognise the importance of supporting ASI and Immunology researchers in Australia and New Zealand. 

We are grateful and proud to introduce our newest ASI Sustaining Member: Nanostring.

About Nanostring

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications.
 

Nanostring's commitment to research


The Singapore Immunology Network (SIgN) & NanoString, in collaboration with Illumina,
co-sponsor a research award for Spatial Biology.
 
The Singapore Immunology Network (SIgN) & NanoString, in collaboration with Illumina, will award the most impactful proposal in cancer immunotherapy research with the ability to discover spatial biomarkers using the latest Digital Spatial Profiling chemistry. The NanoString GeoMx® Cancer Transcriptome Atlas (CTA) for use with the GeoMx® Digital Spatial Profiler (DSP) blends high-plex and spatial analysis in a single experiment. With CTA you can profile over 1,800 genes for every region of interest on your tissue. The read out will be performed with the Illumina NextSeq™ 2000 Sequencing System located at NanoString’s premises.

The grant is open to researchers across Asia Pacific (excluding main land China/Hong Kong/Macau/Taiwan).

To be awarded:
A Cancer Transcriptome Atlas project with NGS readout on Illumina's new NextSeq™ 2000 Sequencing System:

Singapore Immunology Network & NanoString, in collaboration with Illumina, will award the most impactful proposal in cancer immunotherapy research with the ability to discover spatial biomarkers using the latest Digital Spatial Profiling chemistry.

Spatially Resolve the Cancer Transcriptome:

The GeoMx® Cancer Transcriptome Atlas (CTA) for use with the GeoMx® Digital Spatial Profiler (DSP) provides high-plex spatial analysis in a single experiment. The CTA is designed for comprehensive profiling of the tumor, tumor microenvironment, and tumor immune status detecting over 1,800 RNA with spatial resolution.

Apply now with a simple (500 word) abstract to be in with a chance of being awarded a Cancer Transcriptome Atlas project.

Entry date closes 28th September 2020.

Click the green button below to find out more.

Back to All Blogs